Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Which Anticoagulant Class Is Most Effective in Patients with Cancer?
In patients with cancer who develop venous thromboembolism (VTE), guidelines now recommend direct-acting oral anticoagulants (DOACs) over low-molecular-weight heparin (LMWH) due to better efficacy and safety. In a real-world retrospective cohort of 5100 insured patients with various types of cancers (60% with metastatic disease), half received DOACs, one quarter received LMWH, and one quarter received warfarin. Median treatment duration was approximately 3 months.
In propensity-score–weighted analysis, VTE recurrence was significantly less likely in patients who received DOACs than in those who received warfarin or LMWH (20 vs. 30 and 40 VTEs per 100 person-years, respectively). Mortality was significantly lower in DOAC recipients than in LMWH recipients (11 vs. 21 per 100 person-years), as were hospitalizations for bleeding (10 vs. 27 per 100 person-years).
Comment
Although treatment duration in this patient population was short, likely due to disease complexity and patient prognosis, DOAC therapy still showed dramatic efficacy and safety advantages over LMWH for VTE in patients with various types of cancer. DOACs are supported by randomized trials, guidelines, and now real-world data for this indication.
Citation(s)
Author:
Riaz IB et al.
Title:
Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis.
Source:
JAMA Netw Open
2023
Jul
3; [e-pub].
(Abstract/FREE Full Text)
Empfohlen von
Daniel D. Dressler, MD, MSc, MHM, FACP